Cargando...
Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
BACKGROUND: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial or venous thrombosis (or both), and/or pregnancy morbidity in association with the presence of antiphospholipid antibodies. The prevalence of APS is estimated at 40 to 50 cases per 100,000 people....
Gardado en:
| Publicado en: | Cochrane Database Syst Rev |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
John Wiley & Sons, Ltd
2020
|
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094585/ https://ncbi.nlm.nih.gov/pubmed/33045766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012169.pub3 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|